Samaritan files new provisional U.S. patent application for cardiovascular drug, SP-1000

By Lisa Kerner

Erie, Pa., May 23 - Samaritan Pharmaceuticals Inc. filed a new provisional U.S. patent application in support of its original application, adding claims for its cardiovascular drug SP-1000 for the prevention and treatment of cardiovascular disease.

The company said it validated SP-1000's ability to reduce blood cholesterol in animals, clear clogged arteries of atheroma; raise HDL (the "good" cholesterol); and reduce CK enzyme elevations.

Researchers also identified SP-1000's novel mechanism of action in directly targeting cholesterol.

Samaritan cautioned that while SP-1000 is effective in animals, it has not yet been proven effective in people.

Located in Las Vegas, Samaritan discovers, develops and commercializes therapeutics' for AIDS, Alzheimer's, cancer and heart disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.